Tanya Stoyanova

Tanya Stoyanova

Auto-generated profile, based on publicly available information

Tanya Stoyanova

Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
AGAli Ghoochani
Ali Ghoochani
EHEn-Chi Hsu
En-Chi Hsu
MAMerve Aslan
Merve Aslan
MRMeghan A. Rice
Meghan A. Rice
HNHolly M. Nguyen
Holly M. Nguyen
TSTanya Stoyanova
Tanya Stoyanova
Ferroptosis is a type of programmed cell death induced by the accumulation of lipid peroxidation and lipid reactive oxygen species in cells. It has been recently demonstrated that cancer cells are vulnerable to ferroptosis inducers (FIN). However, the therapeutic potential of FINs in prostate cancer in preclinical settings has not been explored. In this study, we demonstrate that mediators of ferroptosis, solute carrier family 7 member 11, SLC3A2, and glutathione peroxidase, are expressed in treatment-resistant prostate cancer. We further demonstrate that treatment-resistant prostate cancer cells are sensitive to two FINs, erastin and RSL3. Treatment with erastin and RSL3 led to a significant decrease in prostate cancer cell growth and migration in vitro and significantly delayed the tumor growth of treatment-resistant prostate cancer in vivo, with no measurable side effects. Combination of erastin or RSL3 with standard-of-care second-generation antiandrogens for advanced prostate cancer halted prostate cancer cell growth and migration in vitro and tumor growth in vivo. These results demonstrate the potential of erastin or RSL3 independently and in combination with standard-of-care second-generation antiandrogens as novel therapeutic strategies for advanced prostate cancer. Significance: These findings reveal that induction of ferroptosis is a new therapeutic strategy for advanced prostate cancer as a monotherapy and in combination with second-generation antiandrogens.

28 August 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
MRMeghan A. Rice
Meghan A. Rice
SMSanjay V. Malhotra
Sanjay V. Malhotra
TSTanya Stoyanova
Tanya Stoyanova
Prostate cancer is the most commonly diagnosed cancer affecting men in the United States. The prostate is a hormone-dependent gland in which androgen hormones testosterone and dihydrotestosterone bind to and activate the androgen receptor, initiating nuclear translocation of androgen receptor and a subsequent signaling cascade. Due to the androgen dependency of the prostate, androgen deprivation therapies have emerged as first line treatment for aggressive prostate cancer. Such therapies are effective until the point at which prostate cancer, through a variety of mechanisms including but not limited to generation of ligand-independent androgen receptor splice variants, or intratumoral androgen production, overcome hormone deprivation. These cancers are androgen ablation resistant, clinically termed castration resistant prostate cancer (CRPC) and remain incurable. First-generation antiandrogens established androgen receptor blockade as a therapeutic strategy, but these therapies do not completely block androgen receptor activity. Efficacy and potency have been improved by the development of second-generation antiandrogen therapies, which remain the standard of care for patients with CRPC. Four second-generation anti-androgens are currently approved by the Food and Drug Administration (FDA); abiraterone acetate, enzalutamide, and recently approved apalutamide and darolutamide. This review is intended to provide a thorough overview of FDA approved second-generation antiandrogen discovery, treatment application, strategies for combination therapy to overcome resistance, and an insight for the potential future approaches for therapeutic inhibition of androgen receptor.

13 January 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
EHEn-Chi Hsu
En-Chi Hsu
MRMeghan A. Rice
Meghan A. Rice
ABAbel Bermudez
Abel Bermudez
FGFernando García-Marqués
Fernando García-Marqués
MAMerve Aslan
Merve Aslan
TSTanya Stoyanova
Tanya Stoyanova
Significance: NEPC is a highly aggressive subtype of prostate cancer that is increasing in incidence, likely due to use of new secondary androgen deprivation therapies. Here, we demonstrate that Trop2 is significantly elevated in CRPC and NEPC and represents a driver of metastatic NEPC. Trop2 overexpression increases tumor growth, drives metastasis and neuroendocrine phenotype, and significantly increases PARP1 levels. Inhibition of PARP1 in Trop2-driven NEPC significantly decreases neuroendocrine features, tumor growth, and metastatic colonization in vivo, suggesting that PARP1 inhibitors may represent a promising therapeutic strategy for metastatic prostate cancer expressing high levels of Trop2.

18 May 2022 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
SLShiqin Liu
Shiqin Liu
BABusola Ruth Alabi
Busola Ruth Alabi
QYQingqing Yin
Qingqing Yin
TSTanya Stoyanova
Tanya Stoyanova

26 July 2022 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
BABusola Ruth Alabi
Busola Ruth Alabi
SLShiqin Liu
Shiqin Liu
TSTanya Stoyanova
Tanya Stoyanova

28 October 2021 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
MAMerve Aslan
Merve Aslan
EHEn-Chi Hsu
En-Chi Hsu
FGFernando García-Marqués
Fernando García-Marqués
ABAbel Bermudez
Abel Bermudez
SLShiqin Liu
Shiqin Liu
TSTanya Stoyanova
Tanya Stoyanova
Breast cancer remains the second most lethal cancer among women in the United States and triple-negative breast cancer is the most aggressive subtype with limited treatment options. Trop2, a cell membrane glycoprotein, is overexpressed in almost all epithelial cancers. In this study, we demonstrate that Trop2 is overexpressed in triple-negative breast cancer (TNBC), and downregulation of Trop2 delays TNBC cell and tumor growth supporting the oncogenic role of Trop2 in breast cancer. Through proteomic profiling, we discovered a metabolic signature comprised of TALDO1, GPI, LDHA, SHMT2, and ADK proteins that were downregulated in Trop2-depleted breast cancer tumors. The identified oncogene-mediated metabolic gene signature is significantly upregulated in TNBC patients across multiple RNA-expression clinical datasets. Our study further reveals that the metabolic gene signature reliably predicts poor survival of breast cancer patients with early stages of the disease. Taken together, our study identified a new five-gene metabolic signature as an accurate predictor of breast cancer outcome.